Nirsevimab immunization's real-world effectiveness in preventing severe bronchiolitis: A test-negative case-control study.

Marta Agüera Aleix Soler-GarciaCarme AlejandreSara Moussalam-MerinoPere Sala-Castellví Gemma Pons Daniel Penela SánchezCarla González-GradoJudit Alsina-RossellCarme ClimentCristina EstevaClàudia FortunyMariona F de-Sevilla Juan-José García-García Pedro Brotons Albert BalaguerJosep EstradaIolanda Jordan-García Carmen Muñoz-Almagro Cristian Launes

Published in: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024)

This study provides real-world evidence of the effectiveness of nirsevimab in preventing RSV-lower respiratory tract infection hospitalization and severe disease in infants during their first RSV season following a systematic immunization program. Immunized patients did not exhibit a higher rate of viral coinfections nor differences in clinical severity once admitted.

Keyphrases

respiratory tract
respiratory syncytial virus
randomized controlled trial
systematic review
end stage renal disease
newly diagnosed
early onset
ejection fraction
prognostic factors
quality improvement
patient reported outcomes